OncoSec Appoints Scientific Advisory Board

OncoSec Appoints Scientific Advisory Board

21 November 2011,   By ,   0 Comments

OncoSec appoints three internationally recognized and respected medical innovators to its newly created Scientific Advisory Board (SAB).

This advisory board is established to provide input into the company’s R&D and clinical strategies, including OncoSec’s multiple planned Phase II clinical trials for the treatment of melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.

Joining the SAB are: Richard Heller, Ph.D. – Director, Frank Reidy Research Center for Bioelectrics, Old Dominion University, Iacob Mathiesen, Ph.D. – CEO, Otivio AS, and Christian H. Ottensmeier, MD, Ph.D. – Professor of Experimental Cancer Research at the University of Southampton.


Real Time Web Analytics